Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593605 | 0.88 | KCNJ1 (0.44) | ALDH1A1KMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL3592162 | 0.88 | ALDH1A1 (0.46) | ALDH1A1KMT2AHTTSMN1; SMN2MAPT | |
| SCHEMBL3594905 | 0.87 | LMNA (0.48) | ALDH1A1SMN1; SMN2MAPTPOLBLMNA | |
| SCHEMBL3602275 | 0.87 | ALDH1A1 (0.41) | ALDH1A1KMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL3596441 | 0.87 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL3595546 | 0.87 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL3594430 | 0.85 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL3595021 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTPOLBKDM4E | |
| SCHEMBL16326419 | 0.85 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL3585791 | 0.85 | ALDH1A1 (0.40) | ALDH1A1KMT2AHTTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | ALDH1A1 4118/4885KMT2A 4721/4885GAA 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.